infectious diseases
/
antibiotic quick reference syndrome-based empiric therapy bacteraemia and endovascular infection bone and joint CNS gastrointestinal sexually transmitted infections HIV and mycobacteria respiratory viruses fungal infections travel and zoonoses infection control and exposures related content in other specialties coming soon
antibiotic quick reference
2- empiric antibiotic quick reference one-page empiric choices by syndrome; triggers for *Pseudomonas*, MRSA, and other add-on cover; escalation checklist8 min
- targeted antibiotic therapy by pathogen preferred agent and oral step-down once cultures return; ESBL, AmpC, CRE, *Pseudomonas*, VRE, *Candida*; coverage gaps8 min
syndrome-based empiric therapy
6- sepsis of unknown source plan undifferentiated sepsis empirics; source identification; resuscitation targets; de-escalation5 min
- community-acquired pneumonia plan severity-stratified empirics by CURB-65; β-lactam + macrolide vs fluoroquinolone; short-course evidence6 min
- urinary tract infections plan cystitis vs pyelonephritis vs complicated UTI; outpatient vs inpatient empirics; ASB pitfalls5 min
- skin and soft tissue infections plan purulent vs non-purulent; cellulitis, abscess, necrotising fasciitis; MRSA decision-making6 min
- intra-abdominal infections plan source control primacy; community vs healthcare-associated empirics; STOP-IT duration5 min
- bacterial meningitis plan time-critical empirics; dexamethasone timing; CSF interpretation; *Listeria* cover indications6 min
fungal infections
1infection control and exposures
1coming soon
1bacteraemia and endovascular infection
2- Staphylococcus aureus bacteraemia plan IDSA/ESCMID 2026 risk stratification; ID consult, TTE/TEE, cefazolin vs cloxacillin (SNAP); duration from first negative culture; SABATO oral step-down4 min
- infective endocarditis Duke-ISCVID 2023; empiric and targeted regimens; surgical indications; POET partial oral therapy; prophylaxis6 min
bone and joint
1CNS
2gastrointestinal
2sexually transmitted infections
2- syphilis staging, serology interpretation, benzathine penicillin by stage, neurosyphilis/ocular/otic, pregnancy and shortage guidance, RPR response, doxy-PEP5 min
- gonorrhoea, chlamydia, and other STIs PHAC 2024 ceftriaxone 500 mg monotherapy, test of cure, chlamydia/LGV, PID, epididymitis, *M. genitalium*, DGI, vaginitis, mpox5 min
HIV and mycobacteria
3- HIV: diagnosis, ART, and prevention 4th-generation testing, baseline workup, rapid-start INSTI regimens, drug interactions, U=U, REPRIEVE statins, pregnancy; Canadian 2025 PrEP/PEP guideline5 min
- HIV opportunistic infections CD4-based differential and prophylaxis; PJP (steroid thresholds), cryptococcal meningitis, toxoplasma, CMV, MAC; ART timing after OIs; IRIS5 min
- tuberculosis TST/IGRA cut-offs, 4R/3HP (Canadian TB Standards 2022), RIPE and toxicities, hepatotoxicity, TB–HIV timing, drug-resistant TB, NTM6 min
respiratory viruses
1travel and zoonoses
2- fever in the returned traveller malaria (CATMAT; IV artesunate via Canadian Malaria Network, primaquine and G6PD), dengue, enteric fever, leptospirosis, rickettsiae, VHF, *Strongyloides* screening5 min
- tick-borne infections Lyme prophylaxis and stages (carditis, neuroborreliosis, arthritis), anaplasmosis, babesiosis3 min
see also
Related notes in other specialties.
in oncology 2 links
- community acquired pneumonia conceptually related to immune checkpoint inhibitor toxicity
- sepsis of unknown source conceptually related to oncologic emergencies